GlassScriptPhysician profile
Dodi Lynn Baum
NPI 1053865576
$2,984.99
in general payments reported to CMS, 2019-2025
25 companies · $316 in 2025
The $316 reported for 2025 was more than what a typical Family provider received nationally (typical 2025 total: $167).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $749 · 2022: $613 · 2023: $748 · 2024: $560 · 2025: $316.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,624.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,623.54 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Tersera Therapeutics LLC | $551.63 | 2021-2025 | Prialt |
| Collegium Pharmaceutical, INC. | $434.29 | 2021-2025 | Xtampza, Belbuca |
| Abbvie INC. | $226.30 | 2021-2025 | |
| Medtronic, INC. | $185.17 | 2024-2025 | Intellis Adaptivestim, Inceptiv, Synchromedii |
| Vertos Medical, INC. | $156.88 | 2021-2022 | |
| Ibsa Pharma INC. | $149.79 | 2021-2024 | Tirosint, Licart, Tirosint |
| Scilex Pharmaceuticals INC. | $145.24 | 2022-2023 | Ztlido |
| Biohaven Pharmaceuticals, INC. | $143.55 | 2021 | |
| Averitas Pharma INC. | $121.85 | 2023-2025 | Qutenza |
| Boston Scientific Corporation | $113.10 | 2022-2024 | |
| Grt US Holding, INC. | $111.18 | 2021-2022 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $106.99 | 2021-2025 | Relistor |
| Electronic Waveform Lab, INC. | $103.93 | 2021-2023 | |
| Protega Pharmaceutials INC | $95.86 | 2022-2023 | Roxybond |
| Redhill Biopharma INC. | $90.71 | 2021-2022 |
Show all 25 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Virtus Pharmaceuticals LLC | $52.44 | 2021 | |
| Alnylam Pharmaceuticals INC. | $33.15 | 2021 | |
| Forte Bio-Pharma LLC | $32.35 | 2021 | |
| Saluda Medical Americas, INC. | $27.53 | 2024 | Evoke |
| Nevro Corp. | $24.64 | 2022-2023 | Senza |
| Bioventus LLC | $22.02 | 2022 | |
| Biodelivery Sciences International, INC. | $16.63 | 2021 | |
| Arbor Pharmaceuticals, INC. | $14.15 | 2021 | |
| Eisai INC. | $13.61 | 2021 | |
| Almatica Pharma LLC | $12.00 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Dodi Baum listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.